Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -10.66% is 349% below its 5-year average of 4.28%, near the low end of its 5-year range (-10.66%–12.75%).
As of the fiscal period ended Tuesday, June 30, 2026. 318.19% below its 12-month average of -2.55%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -10.66%.
RETURN ON EQUITY (ROE)
-10.66%
RETURN ON EQUITY (ROE) AVG TTM
-2.55%
RETURN ON EQUITY (ROE) AVG 3Y
0.99%
RETURN ON EQUITY (ROE) AVG 5Y
4.28%
RETURN ON EQUITY (ROE) AVG 10Y
10.67%
RETURN ON EQUITY (ROE) AVG 15Y
14.78%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-318.19%
CURRENT VS 3Y AVG
-1176.43%
CURRENT VS 5Y AVG
-349.05%
CURRENT VS 10Y AVG
-199.85%
CURRENT VS 15Y AVG
-172.10%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+74.63%
vs the sector median at left
Supernus Pharmaceuticals, Inc.
Market Cap
$2.45B
Return on Equity (ROE)
-10.66%
TTM Avg
-2.55%
3Y Avg
0.99%
5Y Avg
4.28%
Market Cap
$2.41B
Return on Equity (ROE)
-4.88%
TTM Avg
-20.16%
3Y Avg
-52.49%
5Y Avg
-49.61%
Market Cap
$2.41B
Return on Equity (ROE)
-38.17%
TTM Avg
-26.66%
3Y Avg
-25.50%
5Y Avg
23.47%
Market Cap
$2.40B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.52B
Return on Equity (ROE)
-41.10%
TTM Avg
-30.86%
3Y Avg
-32.08%
5Y Avg
-34.60%
Market Cap
$2.37B
Return on Equity (ROE)
41.39%
TTM Avg
43.71%
3Y Avg
5.79%
5Y Avg
-18.90%
Market Cap
$2.35B
Return on Equity (ROE)
-84.78%
TTM Avg
-42.91%
3Y Avg
-54.25%
5Y Avg
-44.36%
Market Cap
$2.33B
Return on Equity (ROE)
71.04%
TTM Avg
-161.38%
3Y Avg
-133.53%
5Y Avg
-111.86%
Market Cap
$2.33B
Return on Equity (ROE)
15.63%
TTM Avg
16.66%
3Y Avg
16.66%
5Y Avg
13.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | $2.45B | -10.66% | -2.55% | 0.99% | 4.28% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | -4.88% | -20.16% | -52.49% | -49.61% |
| Disc Medicine, Inc. (IRON)vs › | $2.41B | -38.17% | -26.66% | -25.50% | 23.47% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | -56.71% | -50.91% | -55.48% | -35.68% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.52B | -41.10% | -30.86% | -32.08% | -34.60% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.37B | 41.39% | 43.71% | 5.79% | -18.90% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -84.78% | -42.91% | -54.25% | -44.36% |
| Liquidia Corporation (LQDA)vs › | $2.33B | 71.04% | -161.38% | -133.53% | -111.86% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 15.63% | 16.66% | 16.66% | 13.72% |
| Privia Health Group, Inc. (PRVA)vs › | $2.58B | 0.00% | 2.68% | 1.94% | -2.51% |
ROE
-10.7%
ROA
-7.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -10.66% |
| 2026-03-31 | -2.69% |
| 2025-12-31 | -3.63% |
| 2025-09-30 | -1.82% |
| 2025-06-30 | 6.06% |
| 2025-03-31 | 6.01% |
| 2024-12-31 | 7.13% |
| 2024-09-30 | 5.93% |
| 2024-06-30 | 0.55% |
| 2024-03-31 | -1.67% |
| 2023-12-31 | 0.14% |
| 2023-09-30 | 2.81% |
| 2023-06-30 | 4.71% |
| 2023-03-31 | 5.71% |
| 2022-12-31 | 6.85% |
| 2022-09-30 | 4.42% |
| 2022-06-30 | 6.83% |
| 2022-03-31 | 8.85% |
| 2021-12-31 | 6.55% |
| 2021-09-30 | 10.09% |
| 2021-06-30 | 12.75% |
| 2021-03-31 | 14.73% |
| 2020-12-31 | 17.04% |
| 2020-09-30 | 18.24% |
| 2020-06-30 | 17.74% |
| 2020-03-31 | 18.95% |
| 2019-12-31 | 18.99% |
| 2019-09-30 | 18.99% |
| 2019-06-30 | 20.07% |
| 2019-03-31 | 21.45% |
| 2018-12-31 | 24.50% |
| 2018-09-30 | 23.41% |
| 2018-06-30 | 22.20% |
| 2018-03-31 | 20.84% |
| 2017-12-31 | 21.42% |
| 2017-09-30 | 23.02% |
| 2017-06-30 | 45.25% |
| 2017-03-31 | 46.92% |
| 2016-12-31 | 47.57% |
| 2016-09-30 | 48.32% |
| 2016-06-30 | 18.34% |
| 2016-03-31 | 14.09% |
| 2015-12-31 | 11.75% |
| 2015-09-30 | 10.46% |
| 2015-06-30 | 34.57% |
| 2015-03-31 | 38.22% |
| 2014-12-31 | 27.85% |
| 2014-09-30 | -10.42% |
| 2014-06-30 | -176.34% |
| 2014-03-31 | -308.14% |
| 2013-12-31 | -275.74% |
| 2013-09-30 | -669.55% |
| 2013-06-30 | -202.73% |
| 2013-03-31 | -134.28% |
| 2012-12-31 | -80.40% |
| 2012-09-30 | 199.81% |
| 2012-06-30 | 139.45% |
| 2011-12-31 | 570.01% |
